190 related articles for article (PubMed ID: 10582871)
1. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study.
McDowell JA; Chittick GE; Ravitch JR; Polk RE; Kerkering TM; Stein DS
Antimicrob Agents Chemother; 1999 Dec; 43(12):2855-61. PubMed ID: 10582871
[TBL] [Abstract][Full Text] [Related]
2. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.
Hughes W; McDowell JA; Shenep J; Flynn P; Kline MW; Yogev R; Symonds W; Lou Y; Hetherington S
Antimicrob Agents Chemother; 1999 Mar; 43(3):609-15. PubMed ID: 10049275
[TBL] [Abstract][Full Text] [Related]
3. A review of the pharmacokinetics of abacavir.
Yuen GJ; Weller S; Pakes GE
Clin Pharmacokinet; 2008; 47(6):351-71. PubMed ID: 18479171
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.
Kumar PN; Sweet DE; McDowell JA; Symonds W; Lou Y; Hetherington S; LaFon S
Antimicrob Agents Chemother; 1999 Mar; 43(3):603-8. PubMed ID: 10049274
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid.
Capparelli EV; Letendre SL; Ellis RJ; Patel P; Holland D; McCutchan JA
Antimicrob Agents Chemother; 2005 Jun; 49(6):2504-6. PubMed ID: 15917556
[TBL] [Abstract][Full Text] [Related]
6. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults.
McDowell JA; Lou Y; Symonds WS; Stein DS
Antimicrob Agents Chemother; 2000 Aug; 44(8):2061-7. PubMed ID: 10898676
[TBL] [Abstract][Full Text] [Related]
7. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.
Wang LH; Chittick GE; McDowell JA
Antimicrob Agents Chemother; 1999 Jul; 43(7):1708-15. PubMed ID: 10390227
[TBL] [Abstract][Full Text] [Related]
8. High-performance liquid chromatographic assay for abacavir and its two major metabolites in human urine and cerebrospinal fluid.
Ravitch JR; Moseley CG
J Chromatogr B Biomed Sci Appl; 2001 Oct; 762(2):165-73. PubMed ID: 11678376
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.
Weller S; Radomski KM; Lou Y; Stein DS
Antimicrob Agents Chemother; 2000 Aug; 44(8):2052-60. PubMed ID: 10898675
[TBL] [Abstract][Full Text] [Related]
10. Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects.
Sadler BM; Chittick GE; Polk RE; Slain D; Kerkering TM; Studenberg SD; Lou Y; Moore KH; Woolley JL; Stein DS
J Clin Pharmacol; 2001 Apr; 41(4):386-96. PubMed ID: 11304895
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, Disposition, and Biotransformation of [
Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R
Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
Darwish M; Nunez R; Youakim JM; Robertson P
Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function.
Izzedine H; Launay-Vacher V; Aymard G; Legrand M; Deray G
Nephron; 2001 Sep; 89(1):62-7. PubMed ID: 11528234
[TBL] [Abstract][Full Text] [Related]
14. Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.
Jullien V; Tréluyer JM; Chappuy H; Dimet J; Rey E; Dupin N; Salmon D; Pons G; Urien S
Br J Clin Pharmacol; 2005 Feb; 59(2):183-8. PubMed ID: 15676040
[TBL] [Abstract][Full Text] [Related]
15. Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis.
Jullien V; Urien S; Chappuy H; Dimet J; Rey E; Pons G; Blanche S; Tréluyer JM
J Clin Pharmacol; 2005 Mar; 45(3):257-64. PubMed ID: 15703361
[TBL] [Abstract][Full Text] [Related]
16. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.
Daluge SM; Good SS; Faletto MB; Miller WH; St Clair MH; Boone LR; Tisdale M; Parry NR; Reardon JE; Dornsife RE; Averett DR; Krenitsky TA
Antimicrob Agents Chemother; 1997 May; 41(5):1082-93. PubMed ID: 9145874
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration.
Calcagno A; Pinnetti C; De Nicolò A; Scarvaglieri E; Gisslen M; Tempestilli M; D'Avolio A; Fedele V; Di Perri G; Antinori A; Bonora S
Br J Clin Pharmacol; 2018 Jun; 84(6):1380-1383. PubMed ID: 29444348
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults.
McDowell JA; Chittick GE; Stevens CP; Edwards KD; Stein DS
Antimicrob Agents Chemother; 2000 Jun; 44(6):1686-90. PubMed ID: 10817729
[TBL] [Abstract][Full Text] [Related]
19. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
[TBL] [Abstract][Full Text] [Related]
20. Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.
van Praag RM; van Heeswijk RP; Jurriaans S; Lange JM; Hoetelmans RM; Prins JM
Clin Infect Dis; 2001 Oct; 33(8):e91-2. PubMed ID: 11565093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
